Peptides MEX / Comparisons
CJC-1295 without DAC vs DAC: identity and albumin binding
DAC denotes a chemical modification enabling albumin binding. Consequently, CJC-1295 without a complete identifier is ambiguous when reading research: a result for the long-acting analogue does not automatically characterize a form without DAC.
Updated · Sources and editorial standards
| Feature | CJC-1295 no DAC | CJC-1295 DAC |
|---|---|---|
| Chemical distinction[1] | Without the DAC unit | With the DAC unit |
| Described albumin binding[1] | Cannot be assigned the DAC mechanism | Documented albumin conjugation |
| Cited human trial[2] | Not characterized by the long-acting trial | Long-acting analogue; GH and IGF-I |
The modification distinguishing the molecules
The FDA technical review separates CJC-1295 from CJC-1295 DAC and distinguishes their salts. It describes an additional unit at the C-terminus of the DAC form. These are not merely two names for different concentrations: the modification changes the entity being characterized.
Sources: [1]
Albumin binding and persistence
The documentation reviews conjugation of CJC-1295 DAC with albumin. That interaction helps explain its investigation as a long-acting GHRH analogue. Without DAC, this persistence mechanism cannot simply be carried over; the family name also does not supply a verified half-life for every presentation.
What the trials actually compared
The Teichman trials studied the long-acting analogue against placebo in healthy adults, measuring exposure, GH and IGF-I. They were not a direct comparison of a commercial without-DAC presentation against a DAC presentation. They also did not measure whether either presentation improved strength or recovery.
Sources: [2]
Questions about this reference
Can the published half-life be assigned to CJC-1295 without DAC?
Not from those trials. The estimate belongs to the studied compound and experimental setting. A without-DAC form would require confirmed identity and its own pharmacokinetic data.
Does an acetate salt indicate the presence of DAC?
No. The document distinguishes the DAC modification from the salt form. Acetate alone does not establish whether the molecule includes the albumin-binding unit.
Sources and original reading
- FDA briefing: CJC-1295-related bulk drug substances, December 2024
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults
Content updated: . How this content is prepared and checked.